Monday, 13 October 2008 | Halifax Live
Advertisement
Home arrow News Listings arrow Health arrow Health Canada Advises Consumers Not to Use Super Fat Burning and LiDa Daidaihua Slimming Capsules fo
Spotlight
Main Menu
Home
Discussion Boards
Metro
Nova Scotia
National
World
News Headlines
News Listings
Video News
Review Listings
Columnist Listings
Reader's Opinion
Media Releases
Links
Contact - News Tips
Search
Sirius Radio
Halifax Beat
Sections
Latest News
Syndicate
Halifax Live News Feed
Health Canada Advises Consumers Not to Use Super Fat Burning and LiDa Daidaihua Slimming Capsules fo Print E-mail
Written by Health Canada   
Wednesday, 05 April 2006
Health Canada is advising consumers not to use two herbal weight loss products from China because they have been found to contain sibutramine, a prescription medication that should only be taken under medical supervision.

Super Fat Burning and LiDa Daidaihua Slimming Capsules are not authorized for sale in Canada. The two products have so far not been found on the Canadian market, but they may have been brought into the country for personal use by travellers or been purchased by Canadians over the Internet.
    
Sibutramine is a prescription medication that suppresses the appetite and is the active ingredient in Meridia (Knoll Pharmaceutical Company). If used improperly, sibutramine can have serious health consequences, including increased heart rate and blood pressure as well as increased pressure to the eyes causing pain and hemorrhaging. Individuals with heart or circulatory problems should not take sibutramine. It should also not be taken with medications such as antidepressants that can affect the level of hormone seretonin in the brain.
    
Consumers who are currently using Super Fat Burning or LiDa Daidaihua Slimming Capsules should stop taking the product immediately and should contact their health care professional for advice.

To date, no adverse reactions from the use of Super Fat Burning and LiDa Daidaihua Slimming Capsules have been reported in Canada. To report a suspected adverse reaction, please contact the Canadian Adverse Drug Reaction Monitoring Program (CADRMP) of Health Canada toll free at:

Telephone: 1 866-234-2345
Facsimile: 1 866-678-6789
 
< Prev   Next >
Our Sponsors
 
Go to top of page Go to top of page
 
Flight Stats
Flight View
| Home | Discussion Boards | Metro | Nova Scotia | National | World | News Headlines | News Listings | Video News | Review Listings | Columnist Listings | Reader's Opinion | Media Releases | Links | Contact - News Tips | Search | Sirius Radio | Halifax Beat |

Halifax Live Archive